Most Immunosuppressive Meds Not Tied to Worse COVID-19 Outcomes
Except for rituximab, no increased risk seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy
Colchicine No Benefit Over Supportive Care for COVID-19
No significant reduction reported in mortality, ventilatory support, ICU admission, length of stay, serious adverse events; increase seen in adverse events, diarrhea
Hospitals Lag in Sexual Harassment Policies
Findings reveal few of the top U.S. medical centers have policies addressing harassment of physicians and staff by patients
Childhood Vaccination Schedule Not Linked to Type 1 Diabetes
Recommended immunization schedule is not positively associated with the incidence of type 1 diabetes in children
Smartphone Wound Follow-Up Increases Odds of Early SSI Diagnosis
Patients in smartphone group had reduced community care attendance, better experiences accessing care after abdominal surgery
FDA Panel Mulls Merck COVID-19 Antiviral Pill
Expert panel will vote later Tuesday on whether to recommend authorizing the drug for high-risk patients
Omicron Variant Spurs New York Officials to Recommend Masking Indoors
So far, there are no confirmed cases of the omicron variant in New York City, according to the health commissioner
Pfizer to Seek FDA Approval of Boosters for Teens Ages 16 to 17
Move to expand booster availability comes as President Joe Biden tries to keep Americans calm about omicron
Regeneron Says Its Antibody Cocktail Likely Weakened by Omicron Variant
No direct data yet available testing the new variant's resistance to immunity from monoclonal antibodies and vaccines
Decline in Infectious Conjunctivitis During COVID-19 Pandemic
Decrease in emergency department encounters for nonallergic conjunctivitis after adoption of public health measures to curb COVID-19
